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Combining drugs, which target different signalling pathways, often decreases adverse side effects while increasing the efficacy of
treatment. The objective of our study was to determine if the combination of our novel atypical retinoic acid metabolism-blocking
agent (RAMBA) VN/66-1 and a promising histone deacetylase inhibitor N-(2-aminophenyl)4-[N-(pyridine-3-yl-methoxy-
carbonyl)aminomethyl]benzamide (MS-275) would show enhanced antineoplastic activity on human PC-3 prostate cancer cells/
tumours and also to decipher the molecular mechanisms of action. The combination of VN/66-1þMS-275 was found to be
synergistic in inhibiting PC-3 cell growth, caused cell cytostaticity/cytotoxicity and induced marked G2/M phase arrest and apoptosis.
In mice with well-established PC-3 tumours, VN/66-1 (5 and 10mgkg
 1day
 1) caused significant suppression of tumour growth
compared with mice receiving vehicle alone. Furthermore, treatment with VN/66-1 (10mgkg
 1day
 1)þMS-275
(2.5mgkg
 1day
 1) for 18 days resulted in an 85% reduction in final mean tumour volume compared with control and was
more effective than either agent alone. Mechanistic studies indicated that treatment of PC-3 cells/tumours with VN/66-1þMS-275
caused DNA damage (upregulation of gH2AX), hyperacetylation of histones H3 and H4, upregulation of retinoic acid receptor-b,
p21
WAF1/CIP1, E-cadherin, and Bad and downregulation of Bcl-2. These data suggest that the mechanism of action of the combination
of agents is DNA damage-induced p21 activation, resulting in inhibition of the Cdc2/cyclin B complex and accumulation of cells in
G2/M phase. In addition, the combination caused modulation and induction of apoptosis. These results suggest that VN/66-1 or its
combination with MS-275 may be a novel therapy for the treatment of prostate carcinoma.
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Prostate cancer (PCa) is the most frequently diagnosed cancer in
American men with an estimated 218890 new cases of the disease
in 2007 (Jemal et al, 2007). Since PCa is one of the leading causes of
deaths worldwide, there is an urgent need to identify effective
agents against this disease. Retinoids, rexinoids, retinoid-related
molecules (RRMs) and histone deacetylase inhibitors (HDACIs)
have shown promising biological activities as single agents in
several preclinical studies of both haematological and solid
malignancies (Altucci and Gronemeyer, 2001; Lindemann et al,
2004; Bolden et al, 2006; Njar et al, 2006a). Because of the
heterogeneous nature of PCa, we hypothesise that agents/
combination of agents affecting various pathways involved in
PCa growth and survival may be advantageous.
It is well noted that ATRA (all-trans retinoic acid), the most
active metabolite of vitamin A is required for the appropriate
differentiation of normal human prostate epithelial cells (Sonneveld
et al, 1998). All-trans retinoic acid undergoes cytochrome P450
metabolism to form inactive polar metabolites (Njar et al, 2006b).
The metabolism of ATRA by CYP enzymes (particularly by CYP26)
and dysregulation of gene expression contribute to the cancerous
phenotype. Treatment of disorders with ATRA often leads to the
development of resistance and is toxic (Freemantle et al, 2003).
In attempts to overcome retinoid resistance in cancer therapy
(Freemantle et al, 2003), our group and others have developed
several retinoic acid metabolism-blocking agents (RAMBAs) that
are currently being investigated in several pre-clinical models of a
variety of cancers and dermatological diseases (Njar et al, 2006b).
Our RAMBAs, however, based on the retinoid scaffold
are considered ‘atypical RAMBAs’, because they are also endowed
with multiple anticancer activities. On the basis of several
studies in our lab, it is now evident that the anticancer activities
of our RAMBAs cannot be explained by inhibition of ATRA
metabolism alone (Patel et al, 2004, 2007b; Gediya et al, 2005;
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sBelosay et al, 2006; Huynh et al, 2006). We recently examined the
growth inhibitory effects of one of our lead atypical RAMBAs VN/
66-1 (Figure 1A) in combination with clinically used suberoyla-
nilide hydroxamic acid (SAHA, a HDACI) on the androgen
receptor-positive human prostate LNCaP cell line (Gediya et al,
2005). An additive growth inhibitory effect was observed. When
tested against other potent RAMBAs and ATRA, VN/66-1 was
found to possess the most favourable pharmacokinetic properties
in mice and was relatively non-toxic (Patel et al, 2007a). This
promising compound may also be effective in hormone-refractory
PCa models.
Histone acetyltransferase and histone deacetylase (HDAC) have
opposing effect on transcription (Kuo and Allis, 1998; Ito and
Adcock, 2002). Often, DNA methylation and histone deacetylation
of tumour suppressor genes occur in many human cancers, leading
to suppression of function of these genes thereby conferring a
growth advantage for the tumour cells (Robertson and Jones, 2000;
Macaluso and Giordano, 2004). Indeed, it has been demonstrated
that the expression and activity of HDAC1 are upregulated (two- to
four-fold) in PCa compared to benign prostatic hyperplasia (Patra
et al, 2001). Histone deacetylase inhibitors, such as SAHA, and
N-(2-aminophenyl)4-[N-(pyridine-3-yl-methoxy-carbonyl)amino-
methyl] benzamide (MS-275) can directly interact with the HDAC
enzymes at the catalytic site and inhibit their function (Marks et al,
2000; Insinga et al, 2005; Bolden et al, 2006). This leads to
acetylation of histones, which opens up the chromatin structure
allowing transcription of antigrowth and proapoptotic genes to
occur. It should be noted that MS-275 is now in phase I/II clinical
trials for various solid tumours and haematological malignancies
(Hess-Stumpp et al, 2007).
Histone deacetylase inhibitors have been reported to have
growth inhibitory activities in PCa models both in vitro and in vivo
(Butler et al, 2000; Nakayama et al, 2001; Gediya et al, 2005). In
addition, HDACIs when combined with retinoids (e.g., ATRA, 9-cis
retinoic acid (9-CRA) or 13-cis-retinoic acid (13-CRA)) display
enhanced (additive) anticancer activities (Pili et al, 2001; Gediya
et al, 2005; Qian et al, 2005, 2007). However, combination
antiproliferative studies with the well-known synthetic retinoid,
N-(4-hydroxyphenyl)retinamide, (4-HPR) have produced conflict-
ing results. Gu et al (2006) clearly demonstrated enhanced
cytotoxic effects with the combination of 4-HPR or other retinoids
and HDACIs, whereas Kuefer et al (2007) reported that sodium
butyrate and 4-HPR administered together antagonise the effects
of each other. Nevertheless, these studies suggest that combina-
tions that include retinoids and HDACIs may have a greater
therapeutic action than treatment with either agent alone.
It is well established that combining drugs, which target
different signalling pathways, can lessen adverse side effects while
increasing the efficacy of treatment (Bevins and Zimmer, 2005;
Verheul et al, 2007). The objective of our study was to determine if
N
O
H
OH
N
N
N
NH2 H
O
N
H
O
O
N
VN/66-1 MS-275
–3 –2 –1 0 1 2 3
0
25
50
75
100
Log [VN/66-1] (M)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
c
o
n
t
r
o
l
)
*** ***
***
** *
***
Control
VN/66-1
VN/66-1+AGN
MS-275
MS-275+AGN
VN/66-1+MS-275
VN/66-1+MS-275+AGN
0
25
50
75
100
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
c
o
n
t
r
o
l
)
0.0 0.1 0.2
0
1
2
3
4
5
6
7
8
9
10
11
12
13
Simultaneous exposure VN/66-1+MS-275
Sequential exposure VN/66-1     MS-275
Antagonism
Synergism
Sequential exposure MS-275      VN/66-1
3 4
MS-275 (M)
V
N
/
6
6
-
1
 
(

M
)
Figure 1 (A) Chemical structures of RAMBA, VN/66-1 and HDAC inhibitor, MS-275. (B) Dose–response curve of VN/66-1 alone and the combination
of VN/66-1 and MS-275 (simultaneous treatment) in PC-3 cells. ’ denotes various concentrations of VN/66-1 alone; m denotes VN/66-1 at various
concentrations plus 0.1mM of MS-275; K shows the effect of 0.1mM MS-275 alone. ***Po0.005; **Po0.01; *Po0.05 (t-test). (C) The effect of
AGN193109 (abbreviated AGN), a pan-RAR antagonist on cell viability (simultaneous treatment). PC-3 cells were treated with 1mM VN/66-1 and/or 0.1mM
MS-275, and 0.1mM AGN193109. ***Po0.0001 (t-test). Data are mean (±s.e.) of at least three independent experiments (B and C). (D) Isobologram
analysis of PC-3 cell growth inhibition by VN/66-1 and MS-275 simultaneously and sequentially. The IC75 values of each drug are plotted on the axes; the
solid line represents the additive effect, while the points represent the concentrations of each compound resulting in 75% growth inhibition. Arrow indicates
sequence of treatment.
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sthe combination of VN/66-1 and MS-275 would show enhanced
(additive or synergistic) antineoplastic activity on hormone-
insensitive human PC-3 PCa cells and to decipher the molecular
mechanisms of action. In the present report, we describe a
synergistic inhibitory effect of MS-275 and our atypical RAMBA
VN/66-1 on the growth of PC-3 cells, and we also describe a
synergistic inhibitory effect of MS-275þVN/66-1 administration
on the growth of well-established PC-3 tumours in a xenograft
model. The antiproliferative effects of these agents alone and in
combination are due to DNA damage-induced modulation of cell
cycle regulatory proteins including p21
WAF1/CIP1 resulting in G2/M
cell cycle arrest and induction of apoptosis via the mitochondrial
pathway. Furthermore, we show that these agents, alone or in
combination, exert their effect on cell growth via retinoid receptor-
independent mechanisms. The novelty of this work arises from
that fact that it is the first mechanistic report of a RAMBA in
combination with an HDACI as a therapeutic for any disorder
including cancer.
MATERIALS AND METHODS
Chemicals and reagents
ATRA was purchased from LKT Laboratories Inc. (St Paul, MN,
USA), while VN/66-1 and MS-275 were synthesised in our
laboratory. AGN193109 was kindly provided by Dr Dianne
Soprano, Temple University, Philadelphia, PA, USA.
Cell culture
The PC-3 (hormone-insensitive PCa) cell line was obtained from
American Type Culture Collection (Rockville, MD, USA). C-81
cells were obtained from the lab of Dr Anne Hamburger and PC3-
AR cells from the lab of Dr Yun Qiu both at the University of
Maryland School of Medicine. Cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA, USA) and 1% penicillin/strepto-
mycin. Cells were grown as a monolayer in T75 or T150 tissue
culture flasks in a humidified incubator (5% CO2, 95% air) at 371C.
Cell growth inhibition (MTT colorimetric assay)
PC-3 cells were seeded in 24- or 96-well plates (Corning Costar) at
a density of 2 10
4 cells per well (24 wells) or 2 10
3 cells per well
(96 wells). Cells were allowed to adhere to the plate for 24h and
then treated with various concentrations of VN/66-1 or MS-275
dissolved in 95% EtOH and 10% DMSO/90% EtOH, respectively.
Cells were treated for 5 days with renewal of test compound and
media on day 3. On the fifth day, medium was renewed and
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide) (Sigma, St Louis, MO, USA) solution (0.5mg MTT per
ml of media) was added to the medium such that the ratio of
MTT:medium was 1:10. The cells were incubated with MTT for
2.5h. The medium was then aspirated and DMSO was added to
solubilise the violet MTT-formazan product. The absorbance at
560nm was measured by spectrophotometry (Victor 1420 multi-
label counter, Wallac, Perkin Elmer, Waltham, MA, USA). For
sequential treatment experiments, cells were treated with the first
agent for 48h, washed and treated with the second agent for
another 48h after which the assay was carried out as described
above. Triplicates were carried out for each concentration and
experiments were independently repeated a minimum of three
times. Results are expressed as percentage of viable cells in
the vehicle-treated control wells. IC50 values were calculated
by nonlinear regression analysis using GraphPad Prism 4.0
(GraphPad Software, San Diego, CA, USA).
Assessment of synergism, additivity or antagonism
The level of interaction (synergistic, additive or antagonistic)
between VN/66-1 and MS-275 was evaluated as described
previously (Chou et al, 1993). Synergism, additivity or antagonism
was quantified by determining the combination index (CI), where
CIo1, CI¼1, and CI41 indicate a synergistic, additive or
antagonistic effect, respectively. Based on the classic isobologram,
the CI was calculated by using the following equation:
CI ¼½ ð DÞ1=ðDxÞ1 þ½ ð DÞ2=ðDxÞ2 
At the 75% inhibition level, (Dx)1 and (Dx)2 are the concentrations
of VN/66-1 and MS-275, respectively, which induce a 75%
inhibition in cell growth. (D)1 and (D)2 are the concentrations
of VN/66-1 and MS-275, which also inhibit cell growth by 75% (as
compared with single agents alone).
Cell cycle analysis
Cells were plated in T-75 flasks containing complete RPMI 1640
medium for 24h. Cells were serum starved after washing with
phosphate-buffered saline (PBS) and incubating with RPMI 1640
(minus phenol red) with 0.2% FBS for 48h. Under these
conditions, cells were arrested in the G0/G1 phase as determined
by flow cytometry. Cells were then stimulated by the addition of
complete RMPI 1640 medium containing 10% FBS. Cells were
treated with VN/66-1 or MS-275 for various times, washed with
PBS, trypsinised, resuspended in 10ml PBS and counted. They
were then centrifuged (10min, 2500r.p.m. at 41C), resuspended in
PBS, fixed in 70% ice-cold ethanol and stored in  201C until
staining. Cells were stained for at least 1h in the dark with a
solution containing 20mgml
 1 propidium iodide (Sigma),
0.02mgml
 1 RNAse and 1 % Triton-X 100 (Sigma). The DNA
content in the treated and mock-treated groups was measured by
flow cytometry analysis using a FACSort flow cytometer (Becton
Dickinson, San Jose, CA, USA); 15000 events were analysed for
each sample. ModFit LT version 3.1 (Verity Software House Inc.,
Topsham, ME, USA) was used to analyse cell cycle distribution.
Flowcytometry for apoptosis detection
Cells were grown in T-75 flasks and treated with various
concentrations of VN/66-1 and MS-275 for different times. Growth
media were collected; cells were typsinzed, pelleted and washed
with PBS. The Annexin V-FITC Apoptosis Detection Kit I was used
to determine the number of early and late apoptotic/necrotic cells
(BD Biosciences, San Jose, CA, USA). Cells were analysed using a
FACSort flow cytometer as mentioned above; 10000 events were
analysed. CellQuest Pro version 5.2.1 (BD Biosciences) was used to
analyse the distribution of cells.
Immunofluorescence
PC-3 cells were grown on eight-chamber glass slides and treated
with various agents for 24h. Immunofluorescence staining was
carried out as described previously (Phatak et al, 2007). After
fixing with methanol:acetone (1:1), cells were stained with
g-H2AX (Upstate, Waltham, MA, USA) and counterstained with
40,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma).
Cells were viewed using a Zeiss Axiovert Fluorescent Microscope
(Carl Zeiss, Gottingen, Germany). Images were processed using
Openlab Volume Deconvolution software for Mac (Improvision,
Lexington, MA, USA).
Quantitative real-time PCR
PC-3 cells were grown in T-75 flasks and were treated with
various agents for 24h. Cells were then harvested and RNA
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sisolated using the RNeasy Mini Kit (Qiagen Inc., Valencia,
CA, USA). cDNA was synthesised using the ReactionReady
First Strand cDNA Synthesis Kit (SuperArray Bioscience Corpora-
tion, Frederick, MD, USA) as directed by the manufacturer.
The RT
2 Real-Time SYBR Green PCR Master Mix and primers
(retinoic acid receptor (RAR)b2, cyclin D1 and b-actin) were also
obtained from SuperArray. qRT–PCR was performed on a
ABI 7900HT machine (Applied Biosystems, Foster City, CA,
USA). The relative levels of RARb2 and cyclin D1 expression
were determined with reference to the internal b-actin control
by calculating 2
 DDCT.
Tumour xenograft studies
All animal studies were performed according to the guidelines
approved by the Institution of Animal Care and Use Committee
(IACUC) of the University of Maryland School of Medicine.
Male SCID mice 4–6 weeks of age (weighing 20–25 g) were
obtained from the National Cancer Institute (Frederick, MD, USA).
Mice were maintained in a controlled environment of light,
humidity and temperature and were given food and water
ad libitum. Subconfluent PC-3 cells were detached using citric
saline, suspended in PBS, centrifuged and resuspended in
Matrigel (BD Biosciences) (10mgml
 1) at 5.0 10
7 cells per ml.
Tumour cells were inoculated subcutaneously into each flank
of the mice. Drug treatment was initiated when tumours
were palpable (B75mm
3). VN/66-1 and MS-275 were suspended
in 0.3% hydroxypropyl cellulose in saline. VN/66-1 (10mgkg
 1)
and MS-275 (2.5mgkg
 1) were administered daily (5 days per
week) by subcutaneous injection. Tumour measurements were
taken twice a week with a digital caliper and mice were weighed
once a week. Tumour volume was calculated by the formula (4/3
pr1
2 r2) with r1 and r2 being the larger and smaller radii,
respectively.
Western blot analysis
For immunoblot detection of various proteins, PC-3 cells were
cultured as described above in T75 flasks. Cells were treated with
VN/66-1 or MS-275 and whole cell lysates were prepared using
lysis buffer containing 0.1 M Tris, 0.5% Triton X-100 and protease
inhibitor. For detection of g-H2AX and Acetyl H3 and H4 (Upstate,
Lake Placid, NY, USA), histones were extracted as described
previously (Phatak et al, 2007). Protein content was determined
using the Bradford Assay (Bio-Rad, Hercules, CA, USA). Protein
was subjected to SDS–PAGE and transferred onto nitrocellulose
membrane. Antibodies against PARP, RARb and E-cadherin were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Antibodies against Bax, Bad, Bcl-2, cdc25C, p-cdc2 (Thr 14) and
p-cdc2 (Tyr 15), and b-actin were purchased from Cell Signaling
(Danvers, MA, USA) and p21 was purchased from Upstate
(Millipore, Billerica, MA, USA). Membranes were then incubated
with secondary antibody (Bio-Rad) at room temperature for 1h.
Bands were visualised by chemiluminescence (Millipore).
Protein expression was normalised to b-actin and densitometry
was carried out using ImageQuant 5.0 (Molecular Dynamics,
Sunnyvale, CA, USA).
Statistical analysis
All experiments were carried out in at least triplicates and are
expressed as mean±s.e. where applicable. Treatments were
compared to controls using the Students’ t-test with either
GraphPad Prism or Sigma Plot. Various treatment groups were
compared using the analysis of variance (ANOVA). P-values less
than 0.05 were considered to be statistically significant.
RESULTS
Effect of VN/66-1 and MS-257 alone or in combination on
PC-3 cell viability
The effect of VN/66-1 and MS-275 on PC-3 cell viability was
examined by the MTT assay (Figure 1B). VN/66-1 inhibited PC-3
cell viability with an IC50 of 2.19mM and MS-275 was found to have
an IC50 of 0.18mM. However, in the combination treatment, there
was a striking shift in the dose–response curve when compared to
VN/66-1 alone (Figure 1B). This was seen after various doses
(0.01–10mM) of VN/66-1 were treated with a low dose of MS-275
(0.1mM, a dose that inhibited cell viability by B20%, Figure 1B).
N-(2-aminophenyl)4-[N-(pyridine-3-yl-methoxy-carbonyl)amino-
methyl]benzamide (0.1mM) significantly enhanced the antiproli-
ferative activity of VN/66-1 by 42000-fold (IC50 from 2.19mM to
o1.0nM).
Since the simultaneous treatment was found to be effective, it
was important to determine whether sequential treatment would
have similar effects. For the sequential treatment, cells were treated
with each compound for 48h. It was found that only the
simultaneous treatment had a synergistic effect in inhibiting
PC-3 cell viability as shown by a classical isobologram (Figure 1C).
Synergism was further assessed by calculating the CI values. A
CIo1, indicative of synergism, was only found for the simulta-
neous treatment (CI¼0.18), while the sequential treatments were
found to be antagonistic (CI¼1.10 for VN/66-1 first; and CI¼1.72
for MS-275 first) at the 75% inhibition level (Table 1). Further-
more, only the simultaneous treatment had a synergistic effect at
all three (50, 75 and 90%) inhibition levels.
Based on these results, cells were treated at concentrations,
which correspond to a 75% level of inhibition (10mM VN/66-1 and
5mM MS-275) for all subsequent experiments unless otherwise
stated. Because the combination was found to be synergistic, these
concentrations were halved for simultaneous treatments (5mM VN/
66-1þ2.5mM MS-275). This concentration of VN/66-1 is biologi-
cally relevant, because it is well below the maximum plasma
concentration (26.9mM), which was achieved in mice following a
single subcutaneous administration of 10mgkg
 1 of VN/66-1
(Patel et al, 2007a). It should also be noted that these concentra-
tions of MS-275 have been used previously for a similar study
using PC-3 cells (Chen et al, 2005). Furthermore, it has been
reported that MS-275 has an IC50 value of 4.8mM in inhibiting
HDAC activity in nuclear extracts (Miller et al, 2003).
We also tested PC3-AR cells, PC-3 cells infected with the
androgen receptor and C-81 cells (high passage LNCaP cells)
(Igawa et al, 2002) to see if they responded to the same extent as
the PC-3 cells. Since PC-3 cells are known to be AR-negative and
clinically most prostate tumours express the AR, it was important
to determine if the effects of the combination treatment were
independent of AR status. We found that the IC50 for the
combination of VN/66-1þMS-275 (various concentrations of
VN/661-1þ0.1mM MS-275) in the PC3-AR cells was 370nM
(dose–response curve not shown). Similar results were obtained
with C-81 cells (data not shown). It is evident that the combination
is effective independent of AR status of the PCa cells.
Table 1 Combination index values for the three drug combinations at
50, 75 and 90% inhibition levels on PC-3 cell viability
CI values
Drug combination 50% 75% 90%
VN/66-1+MS-275 0.56 0.18 0.24
VN/66-1-MS-275 1.85 1.10 0.69
MS-275-VN/66-1 0.56 1.72 4.74
Arrows indicate the sequence of treatment.
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sPC-3 cell growth inhibition by VN/66-1 or MS-275 or their
combination is independent of retinoid receptors
Previously we had shown that VN/66-1 does not bind to or cause
transactivation of the RARs (a, b or g) (Patel et al, 2007b). To
further examine the role of the RARs in the mechanism of action of
either VN/66-1 or MS-275, we tested the effect of these agents in
combination with AGN193109, a pan-RAR antagonist (Agarwal
et al, 1996). AGN193109 did not have any effect on 1mM of VN/66-
1, 0.1mM of MS-275 or the combination (Figure 1D). Thus, we
conclude that neither VN/66-1 nor MS-275 require the RARs to
exert their growth inhibitory effects. However, this is not to say
that the RARs are not involved in the mechanism of action of these
agents, it only shows that the RARs are not necessary. This
complements findings reported for the most active metabolite of
4-HPR, 4-oxo-fenretinide (4-oxo-4-HPR) (Villani et al, 2006) and
the unhydrolyzable fenretinide analog, 4-hydroxybenzylretinone
(Anding et al, 2007). It is important to note that VN/66-1 is
structurally similar to these RRMs.
Effects of VN/66-1 and MS-275 on cell cycle and
proliferation
VN/66-1 and MS-275 alone as well as the combination were found
to induce a strong G2/M phase arrest of the cell cycle when
compared to vehicle-treated cells (Figure 2A–D). Previously,
studies have reported that HDACIs generally induce a G1 phase
arrest at lower concentrations and a G2/M phase arrest at higher
concentrations (Richon et al, 2000; Lindemann et al, 2004). We
confirmed that the cells were indeed not arrested in G1 by looking
at cyclin D1 mRNA levels by RT–PCR, a marker for G1 phase
arrest. We found that cyclin D1 mRNA levels were not significantly
altered after treatment with either of the agents or the combination
(data not shown). Furthermore, an increase in p21
WAF1/CIP1
(hereafter referred to as p21), the cyclin-dependent kinase
inhibitor, was observed. This is especially important since p21
has been known to be involved in the ability of HDACIs to block
proliferation (Acharya et al, 2005). p21 protein expression was
found to be upregulated (9.25-fold) with MS-275 alone and even
more (10-fold) in the combination of VN/66-1 and MS-275
(Figure 3D).
Both agents alone and the combination of VN/66-1 and MS-275
were found to be cytostatic and cytotoxic. A cell count over time
revealed that while vehicle treated cells continued to proliferate,
cells in the three treatment groups did not (Figure 3A).
Furthermore, the number of late apoptotic and necrotic cells
increased over time in the three treatment groups. Apoptotic
control cells remained fairly constant until 72h at which time these
cells were most likely dying from depleted serum levels in the
media (Figure 3B). This indicated that the cells were actually dying
after treatment with VN/66-1 or MS-275 alone and with the
combination of both agents. Taken together, these data suggest
that that cell cycle arrest followed by apoptosis leads to the
reduced PC-3 cell survival that was observed.
Treatments with VN/66-1 or MS-275 or their combination
reactivate RARb2
Retinoic acid receptor-b2, a known tumour suppressor gene,
which has been shown to be silenced in PC-3 cells (Nakayama et al,
2001). N-(2-aminophenyl)4-[N-(pyridine-3-yl-methoxy-carbonyl)
aminomethyl]benzamide has previously been shown to reactivate
RARb2 in a variety of cell lines including prostate, renal carcinoma
and breast cancer cells (Hess-Stumpp et al, 2007). We found that
while MS-275 alone induced more than a three-fold increase in
RARb2 expression, the combination induced almost a seven-fold
increase as determined by RT–PCR (Figure 3C).
Effect of VN/66-1 and MS-275 on PC-3 cell protein
expressions
The levels of histone acetylation in PC-3 cells were determined
after a 24h treatment. Histones were isolated and western blot
analysis revealed that there was an increase in acetylated histones 3
and 4 in the MS-275 and combination-treated cells (Figure 3D).
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Figure 2 Percent of PC-3 cells in each phase of the cell cycle. (A) Control; (B) VN/66-1 (10mM); (C) MS-275 (5mM); (D) VN/66-1þMS-275
(5þ2.5mM, respectively). ’ represents the cells in the G0/G1 phase; m represents cells in the S phase; . represents cells in the G2/M phase of the cell
cycle.
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cells that are RARb negative (LNCaP, PC-3 and DU-145 PCa cell
lines) have been shown to be hypoacetylated at H3 and H4
(Nakayama et al, 2001). This is another reason why combining an
HDACI with a RAMBA is especially important for PCa treatment.
Furthermore, deacetylation of these two histones around the
promoter region has also been implicated in the silencing or
inactivation of p21 (Gui et al, 2004; Ocker and Schneider-Stock,
2007).
A general screen to determine whether apoptosis was occurring
via the mitochondrial pathway revealed that Bad levels were
increased and Bcl-2 levels were decreased in the combination-
treated group (Figure 3D). Furthermore, staining cells with
Annexin V/FITC and PI revealed that there was a time-dependent
increase in the number of early (Annexin V-FITC positive, PI
negative; (data not shown)) and late (Annexin V-FITC and
PI positive) apoptotic cells after treatment with VN/66-1 and/or
MS-275 (Figure 3B).
VN/66-1 in combination with MS-275 induces strong DNA
damage
The phosphorylation of histone variant H2AX, g-H2AX was
observed by immunofluorescent staining of PC-3 cells after a
24h treatment with the agents. g-H2AX, which is a maker for DNA
damage, was found to be expressed in all three treatment groups,
but strong foci were only seen in the combination group (Figure 4).
When g-H2AX-stained cells were overlaid with DAPI-stained cells,
it was apparent that the nucleus was intact and the DNA damage
was occurring within the nucleus. The occurrence of DNA damage
was confirmed by western blot analysis with the g-H2AX antibody
(Figure 3D).
The combination of VN/66-1 and MS-275 shows an
inhibitory effect on PC-3 prostate tumour growth in vivo
To demonstrate therapeutic activity of VN/66-1þMS-275, an
in vivo antitumour study was conducted. PC-3 xenografts were
grown in male SCID mice and treated with 10mgkg
 1 of VN/66-1
or 2.5mgkg
 1 of MS-275 or the combination of the two
(subcutaneous administration). An initial dose–response study
was performed to determine which doses of VN/66-1 and MS-275
would be best for the study. Three doses each of VN/66-1 (5, 10
and 20mgkg
 1) and MS-275 (5, 10 and 15mgkg
 1) were
examined in a PC-3 xenograft model (data not shown). The
purpose of the dose response study was to select a dose, which was
not only effective in inhibiting tumour growth but also displayed
minimal toxicity in the mice. Moderate weight loss was observed
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Figure 3 (A) Cell count over time after treatment of PC-3 cells. VN/66-1 (10mM), MS-275 (5mM) and the combination VN/66-1þMS-275 (5þ2.5mM)
were used, respectively. Po0.001 for 18–72h vs control (ANOVA) (two-way ANOVA was carried out and most time points were found to be significantly
different for different treatments, but values are not reported here). (B) The percent of late apoptotic/necrotic cells as determined by Annexin V-FITC and
PI positive staining by flow cytometry. ***Po0.001 compared to control;
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compared to MS-275 (ANOVA). (C) RARb mRNA expression after treatment of PC-3 cells for 24h. *Po0.01 and **Po0.001 vs control and VN/66-1
alone (t-test). Data are mean (±s.e.) of three independent experiments (A–C). (D) Western blot analysis after treatment of PC-3 cells for 24h (p21,
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were used for subsequent experiments.
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were noted with either compound. Based on the results that
5mgkg
 1 was very effective in inhibiting tumour growth, we
decided to use even a lower dose for the combination study; hence,
2.5mgkg
 1 was administered for MS-275 alone in combination
with 10mgkg
 1 of VN/66-1.
We found that the combination of VN/66-1 and MS-275 was the
most efficacious and inhibited PC-3 tumour growth by more than
85% (Figure 5A). The mean change in tumour volume data
corresponded well with the mean tumour weights for each group
(Figure 5C). Furthermore, no overt weight loss was seen in any of
the treatment groups (Figure 5B). Although it may appear that the
combination group had lower mean body weights than the other
groups, it is important to note that this group had the lowest body
weights at the start of the treatment. A dotted line is drawn from
20g on Figure 5B to clarify this. These in vivo results confirm
our in vitro results that VN/66-1 and MS-275 in combination
inhibit cell and tumour growth more effectively than either of the
agents alone.
Effect of treatment on PC-3 tumour protein expressions
Loss of E-cadherin, which is involved in adhesion between
epithelial cells has been associated with tumour progression and
metastasis (Mareel and Leroy, 2003). Thus, E-cadherin upregula-
tion is often associated with increased differentiation of cancer
cells. Immunoblot analysis with the tumour samples revealed that
there was an increase in E-cadherin expression to some extent in
the treatment groups (Figure 5C). Expression of p21 was also
upregulated as was previously seen in whole cells. Since we had
earlier demonstrated that apoptosis was taking place in vitro,w e
wanted to confirm if it was taking place in vivo. Thus, we examined
the cleavage of PARP, and expression of Bax, Bad and Bcl-2.
Although low levels of PARP cleavage was seen in the control
tumours at a basal level, which is often associated with tumours,
higher levels of the cleaved fragment (89kDa) were observed in the
treatment groups. Bax and Bad levels, which are both proapoptotic
proteins, were elevated in the combination groups. Bcl-2, an
antiapoptotic protein was found to have decreased levels in
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Figure 4 Immunocytochemistry performed with PC-3 cells after a 24h treatment to determine the occurrence of DNA damage. Concentrations used
are as follows: VN/66-1 (10mM), MS-275 (5mM) and the combination VN/66-1þMS-275 (5þ2.5mM), respectively.
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support our proposed mechanism that apoptosis is taking place
via the intrinsic pathway.
To further examine the occurrence of the G2/M phase arrest, the
protein expression of various G2/M transition markers was
assessed. It has been established that inhibitory phosphorylation
of Cdc2 on Thr 14 and Tyr 15 causes the accumulation of inactive
cyclin B1/Cdc2 complex (Mueller et al, 1995). Thus, we examined
the expression of p-Thr 14 and p-Tyr 15 in the tumours. Both
proteins showed increased levels in the combination treatment
group. Cdc25C, a phosphatase that mediates the conversion of
Cdc2 from an inactive to an active form was found to have
unchanged levels in the tumours (Figure 5D). These data suggest
that G2/M arrest is taking place in the tumours as well.
Protein expression of tumour suppressor gene, RARb was found
to be increased in the tumours of the VN/66-1 and combination-
treated animals (Figure 5D). This is especially important because
protein expression of RARb could not be detected in whole cells,
which is why mRNA expression was determined by a more
sensitive method in these cells. Thus, it is quite significant that
RARb protein expression could be detected in the tumours.
DISCUSSION
In the present study, we demonstrated, for the first time, a synergistic
inhibitory effect of a RAMBA VN/66-1 and MS-275 on the growth of
hormone-insensitive human PC-3 PCa cells and tumours. We also
present data to suggest the mechanisms of action of these agents. A
few studies have been carried out combining MS-275 and isomers of
ATRA (9-CRA or 13-CRA) as recently reported in a review by Hess-
Stumpp et al (2007). Although these two compounds have exhibited
additive effects with MS-275, the therapy may be problematic for
chronic use because of potential development of resistance due to
induction of ATRA metabolism CYP26 enzymes (Freemantle et al,
2003; Njar et al, 2006b). In contrast, the combination of VN/66-1 and
MS-275 is unlikely to succumb to this potential side effect, because
VN/66-1 is a potent RAMBA and does not induce CYP26 enzymes in
cancer cells (Patel et al,2 0 0 4 ;H u y n het al,2 0 0 6 ) .A d d i t i o n a l l y ,w e
have shown that while ATRA causes alopecia, skin scaling and loss
of body weight at relatively low doses, VN/66-1 does not exhibit
these toxic events even at doses as high as 45.7mgkg
 1day
 1 for 14
consecutive days in mice (Patel et al, 2007a).
In this study, we examined the combinatorial effects of VN/66-1
and MS-275 in hormone-refractory PC-3 cells. We observed that
the two agents, when administered simultaneously, had a
synergistic effect in inhibiting PC-3 cell growth. We also studied
the effects of each sequential treatment, VN/66-1 first and then
MS-275 first. Although the sequential treatments showed anta-
gonistic effects, this is not the first time a sequential treatment with
an HDACI has been found to be antagonistic, which was found to
be due to conflicting signalling pathways (Kuefer et al, 2007). This
portrays the importance of careful investigation into the effects of
combination treatments and why it should not be assumed that,
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Figure 5 (A) The effect of VN/66-1 (10mgkg
 1), MS-275 (2.5mgkg
 1) and the combination (10þ2.5mgkg
 1, respectively) in a PC-3 xenograft model
in male SCID mice. Mice (n¼5) were injected subcutaneously QD, tumours were measured twice a week. Statistical significance was determined by the
t-test. *Po0.05. Data are mean (±s.e.) (B) mean body weights. Mice were weighed once a week for the duration of the study. The dotted line at 20g
shows that the mice in the combination group weighed less than the mice in the other groups at the start of the study. (C) Mean tumour weights taken upon
killing all mice and collecting tumours. *Po0.05. Data are mean (±s.e.). (D) Western blot analysis of protein expression in PC-3 tumours taken from mice.
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effective in combination (Bevins and Zimmer, 2005; Hurtubise and
Momparler, 2006).
We went on to show that both agents alone and in combination
induced a G2/M phase arrest of the cell cycle in PC-3 cells. We also
found that the combination was cytostatic as well as cytotoxic by
blocking proliferation and inducing apoptosis. Together, these
data suggest that cell cycle arrest followed by apoptosis leads to the
reduced cell survival observed in the PC-3 cells. We propose that
apoptosis is occurring via the mitochondrial pathway (intrinsic)
based on the increased protein expression of Bad and decreased
protein expression of Bcl-2. Retinoic acid receptor-b2, a tumour
suppressor gene silenced in the PC-3 cells, was found to be
reactivated and had approximately a seven-fold increase in mRNA
levels in the combination-treated cells. DNA damage was also
found to take place rather strongly in the VN/66-1þMS-275 group
after a 24h treatment. A marked increase in histone 3 and 4
acetylation was also observed after a 24h treatment, as was
increased protein expression of p21. Acetylation of these two
histones can be directly linked to RARb2 reactivation and p21
activation, since promoters of these genes have been found to be
deacetylated at H3 and H4 (Lotan et al, 2000; Gui et al, 2004).
In vivo studies confirmed the in vitro results and showed that VN/
66-1 (10mgkg
 1) in combination with MS-275 (2.5mgkg
 1)i sv e r y
effective in suppressing PC-3 tumour growth. It is important to point
out that although the combination is additive in vivo at the doses
used, higher doses would produce a synergistic effect. Furthermore, a
slightly higher dose may completely prevent further growth of the
initial tumours in the combination group. Even the doses used in this
study are extremely effective in inhibiting tumour growth, moreover,
no overt toxicity such as alopecia, skin scaling, loss of body weight or
mortality was observed in the combination group. An increase in the
protein expression of Bad and decrease in the expression of Bcl-2
coupled with PARP cleavage suggests that the mechanism of
apoptosis is via the intrinsic pathway. Differentiation was also
observed by an increase in E-cadherin protein expression in the
treatment groups. Retinoic acid receptor-b and p21 protein
expression were also upregulated in the combination treatment
tumours. G2/M transition markers were examined in tumours to
confirm the G2/M arrest seen in cells.
As summarised in Figure 6, the mechanism of action of the
combination appears to be through the induction of DNA damage,
which is known to activate p21. Activated p21 then inhibits the
Cdc2/cyclin B complex, which is required for G2/M progression
(Weinberg, 2007). Furthermore, it has previously been shown that
p21 and p53 are necessary to maintain a G2 arrest following DNA
damage (Bunz et al, 1998). However, it is clear in this study that
p21 induction is taking place in a p53-independent manner in PC-3
cells, since it is well established that this cell line carries mutated
p53 (Horoszewicz et al, 1980). This accounts for the G2/M arrest,
which is seen in the cells. Acetylation of histones H3 and H4 also
contributes to p21 activation as well as to RARb activation. This
cell cycle block in conjunction with apoptosis and RARb activation
leads to eventual inhibition of PC-3 cell and tumour growth. The
wide arrays of the anticancer properties of the two agents indicate
that the biological mechanisms of actions of these agents are
diverse thus making them more attractive for pre-clinical and
clinical development for the treatment of PCa.
In conclusion, we have found a potent combination, which is
effective against hormone-refractory PCa cells and tumours. This
combination of RAMBA VN/66-1 and HDACI MS-275 is highly
effective in inhibiting PC-3 cell and tumour growth. In the near
future, we plan to repeat the in vivo study with oral dosing, since
MS-275 is orally bioavailable and is a preferred route of
administration (Hess-Stumpp et al, 2007). Additionally,
we propose to further investigate the mechanism of induction of
DNA damage. These are the first studies to specifically explore the
anticancer activities and biological mechanisms of VN/66-1 in
combination with MS-275 in PCa. On the basis of these profound
results, further pre-clinical studies are warranted to develop the
combination of VN/66-1 and MS-275 for the treatment of PCa.
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